{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:56:25Z","timestamp":1792680985204,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This multicenter, parallel-arm, superiority, randomized, double-blind, placebo-controlled study evaluates the efficacy of Totum-63 (T63), a polyphenol-rich blend of plant extracts, in improving fasting plasma glucose (FPG) in individuals with prediabetes or early-stage type 2 diabetes (T2D). Individuals from seven European countries with FPG between 110-220\u2009mg\/dL were randomized to receive placebo (PBO, n\u2009=\u2009210), T63 (5\u2009g\/d) distributed thrice daily (T63 TID, n\u2009=\u2009212) or twice daily (T63 BID, open-label arm, n\u2009=\u2009214) over six months. Individuals were randomly assigned using a dynamic randomization algorithm, stratified by their glycemic status at baseline (FPG\u2009&lt;\u2009126\u2009mg\/dL or FPG\u2009\u2265\u2009126) and the investigational site country. The primary outcome was the FPG change in T63 TID compared to PBO in the intention-to-treat population. Secondary assessments included changes in diabetes biomarkers, lipid profile, anthropometric measurements and subpopulation analyses based on glycemic status. During the whole study, neither the investigators nor the subjects were aware of the product they tested, except in the open arm. After six months, FPG was significantly reduced in the T63 TID group (PBO-adjusted mixed model estimated difference, PBO-AD\u2009=\u2009\u22123.8\u2009mg\/dL, 95% CI: [\u22125.9; \u22121.7], p\u2009=\u20090.0149) and the T63 BID group (PBO-AD\u2009=\u2009\u22125.5\u2009mg\/dL, 95% CI: [\u22129.7; \u22121.3] p\u2009&lt;\u20090.001). Hence, T63 may represent a non-pharmaceutical strategy for T2D prevention. ClinicalTrials.gov Identifier: NCT04423302. Funding: This trial was funded by Valbiotis\u00ae.<\/jats:p>","DOI":"10.1038\/s41467-026-75626-0","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:56:18Z","timestamp":1784552178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Totum-63, a plant-based polyphenol-rich extract, in prediabetes or early-stage type 2 diabetes: an international, multicenter, randomized controlled trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0761-3355","authenticated-orcid":false,"given":"Vivien","family":"Chavanelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"F. Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Fayat Cazaubiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Bard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-7161","authenticated-orcid":false,"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Sapone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Bouchard-Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Bargetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-1163","authenticated-orcid":false,"given":"Nathalie","family":"Boisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-5799","authenticated-orcid":false,"given":"Bruno","family":"Guigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Le Joubioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Maugard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-0799","authenticated-orcid":false,"given":"Pascal","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-5973","authenticated-orcid":false,"given":"Andr\u00e9","family":"Marette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"75626_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.  Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"75626_CR2","doi-asserted-by":"crossref","unstructured":"Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"75626_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.7812\/TPP\/14-002","volume":"18","author":"P Tuso","year":"2014","unstructured":"Tuso, P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm. J. 18, 88\u201393 (2014).","journal-title":"Perm. J."},{"key":"75626_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/2047487319880041","volume":"26","author":"J Beulens","year":"2019","unstructured":"Beulens, J. et al. Risk and management of pre-diabetes. Eur. J. Prev. Cardiol. 26, 47\u201354 (2019).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"75626_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/1535370220915644","volume":"245","author":"A Sallar","year":"2020","unstructured":"Sallar, A. & Dagogo-Jack, S. Regression from prediabetes to normal glucose regulation: State of the science. Exp. Biol. Med. Maywood NJ 245, 889\u2013896 (2020).","journal-title":"Exp. Biol. Med. Maywood NJ"},{"key":"75626_CR6","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2337\/dc22-2376","volume":"46","author":"MR Rooney","year":"2023","unstructured":"Rooney, M. R. et al. Global Prevalence of Prediabetes. Diab Care 46, 1388\u20131394 (2023).","journal-title":"Diab Care"},{"key":"75626_CR7","doi-asserted-by":"publisher","first-page":"E1119","DOI":"10.1152\/ajpendo.00629.2020","volume":"320","author":"V Chavanelle","year":"2021","unstructured":"Chavanelle, V. et al. Effects of Totum-63 on glucose homeostasis and postprandial glycemia: a translational study. Am. J. Physiol. -Endocrinol. Metab. 320, E1119\u2013E1137 (2021).","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"key":"75626_CR8","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41366-021-00870-x","volume":"45","author":"HJP van der Zande","year":"2021","unstructured":"van der Zande, H. J. P. et al. Effects of a novel polyphenol-rich plant extract on body composition, inflammation, insulin sensitivity, and glucose homeostasis in obese mice. Int. J. Obes. 45, 2016\u20132027 (2021). 2005.","journal-title":"Int. J. Obes."},{"key":"75626_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nutres.2023.07.010","volume":"118","author":"V Chavanelle","year":"2023","unstructured":"Chavanelle, V. et al. A novel polyphenol-rich combination of 5 plant extracts prevents high-fat diet-induced body weight gain by regulating intestinal macronutrient absorption in mice. Nutr. Res. N. Y. N. 118, 70\u201384 (2023).","journal-title":"Nutr. Res. N. Y. N."},{"key":"75626_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.numecd.2022.04.001","volume":"32","author":"V Chavanelle","year":"2022","unstructured":"Chavanelle, V. et al. Impact of TOTUM-63, a fibre and polyphenol rich plant-based composition, on gut and pancreatic hormone secretion in diet-induced obese mice. Nutr. Metab. Cardiovasc. Dis. NMCD 32, 1797\u20131807 (2022).","journal-title":"Nutr. Metab. Cardiovasc. Dis. NMCD"},{"key":"75626_CR11","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.3390\/ijms24043652","volume":"24","author":"Q Haguet","year":"2023","unstructured":"Haguet, Q. et al. Inhibitory potential of \u03b1-amylase, \u03b1-glucosidase, and pancreatic lipase by a formulation of five plant extracts: TOTUM-63. Int. J. Mol. Sci. 24, 3652 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"75626_CR12","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1111\/dom.14817","volume":"24","author":"P Sirvent","year":"2022","unstructured":"Sirvent, P. et al. TOTUM-63, a plant-based polyphenol-rich extract, improves glycaemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial. Diab Obes. Metab. 24, 2331\u20132340 (2022).","journal-title":"Diab Obes. Metab."},{"key":"75626_CR13","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s11606-013-2548-4","volume":"28","author":"NM Maruthur","year":"2013","unstructured":"Maruthur, N. M. et al. Early Response to Preventive Strategies in the Diabetes Prevention Program. J. Gen. Intern. Med. 28, 1629\u20131636 (2013).","journal-title":"J. Gen. Intern. Med."},{"key":"75626_CR14","unstructured":"Zhao, T. et al. Effects of exercise, metformin and their combination on glucose metabolism in individuals with abnormal glycaemic control: a systematic review and network meta-analysis. Br. J. Sports Med. bjsports-2024-108127 (2024)."},{"key":"75626_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2337\/dc06-1392","volume":"30","author":"GA Nichols","year":"2007","unstructured":"Nichols, G. A., Hillier, T. A. & Brown, J. B. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diab Care 30, 228\u2013233 (2007).","journal-title":"Diab Care"},{"key":"75626_CR16","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.2337\/dcS15-3000","volume":"39","author":"J Tuomilehto","year":"2016","unstructured":"Tuomilehto, J. & Schwarz, P. E. H. Preventing diabetes: Early versus late preventive interventions. Diab Care 39, S115\u2013S120 (2016).","journal-title":"Diab Care"},{"key":"75626_CR17","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0140-6736(05)60424-2","volume":"352","author":"PBS Fowler","year":"1998","unstructured":"Fowler, P. B. S. The UK prospective diabetes study.  Lancet 352, 1933 (1998).","journal-title":"Lancet"},{"key":"75626_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin, E. et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 141, 421\u2013431 (2004).","journal-title":"Ann. Intern. Med."},{"key":"75626_CR19","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.2337\/dc06-0560","volume":"29","author":"RF Hamman","year":"2006","unstructured":"Hamman, R. F. et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diab Care 29, 2102\u20132107 (2006).","journal-title":"Diab Care"},{"key":"75626_CR20","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes\u20132024. Diabetes Care 47, S145\u2013S157 (2023).","DOI":"10.2337\/dc24-S008"},{"key":"75626_CR21","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies, M. J. et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care 45, 2753\u20132786 (2022).","journal-title":"Diab Care"},{"key":"75626_CR22","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/archinte.167.10.1068","volume":"167","author":"PWF Wilson","year":"2007","unstructured":"Wilson, P. W. F. et al. Prediction of incident diabetes mellitus in middle-aged adults: The Framingham offspring study. Arch. Intern. Med. 167, 1068\u20131074 (2007).","journal-title":"Arch. Intern. Med."},{"key":"75626_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499\u2013502 (1972).","journal-title":"Clin. Chem."},{"key":"75626_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985).","journal-title":"Diabetologia"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75626-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75626-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75626-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:05:52Z","timestamp":1787569552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75626-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75626"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75626-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The test item (Totum-63) was provided by Valbiotis. VC, MFC, and FLJ are Valbiotis employees, PS is Valbiotis Chief Scientific Officer, SP is Valbiotis Chief Executive Officer. YFO, VS, ABM, and MB are former Valbiotis employees. TM, BG, SH, and JMB are members of Valbiotis\u2019 scientific and medical board. NB and AM are former members of Valbiotis\u2019 scientific and medical board. BP declares no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8844"}}